Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 1 paper. Top paper: “Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults With Anti-acetylcholine Receptor Antibody-positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-label Extension”.
Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Andreas Meisel, Michael Nicolle +5 more